Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice

Xing Guo Wang, Thomas Jandl, Ekaterina Dadachova, Ekaterina Revskaya

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Background: There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. Results: CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC 50 of 120 ng/ml. 125I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4% ID/g at 2 h post-injection. Both naive and 200 μCi 188Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. Conclusion: rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.

Original languageEnglish (US)
Pages (from-to)139-147
Number of pages9
JournalTherapeutic Delivery
Volume5
Issue number2
DOIs
StatePublished - Feb 1 2014

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice'. Together they form a unique fingerprint.

  • Cite this